A Pilot Study Using Simvastatin in the Treatment of Nonalcoholic Steatohepatitis

Journal of Clinical Gastroenterology - Tập 43 Số 10 - Trang 990-994 - 2009
Austin Nelson1, Dawn M. Torres2, Ana E. Morgan3, Christopher Fincke2, Stephen A. Harrison2
1Department of Internal Medicine, Wilford Hall Medical Center, Lackland Air Force Base
2Division of Gastroenterology
3Department of Internal Medicine, Brooke Army Medical Center, Fort Sam Houston, TX

Tóm tắt

Từ khóa


Tài liệu tham khảo

Machado, 2006, Hepatic histology in obese patients undergoing bariatric surgery, J Hepatol, 45, 600, 10.1016/j.jhep.2006.06.013

Wanless, 1990, Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors, Hepatology, 12, 1106, 10.1002/hep.1840120505

Harrison, 2004, Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, Clin Liver Dis, 8, 861, 10.1016/j.cld.2004.06.008

Defronso, 1991, Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease, Diabetes Care, 14, 173, 10.2337/diacare.14.3.173

Day, 1998, Steatohepatitis: a tale of two “hits”? [editorial], Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2

Kaplan, 1998, Leptin, obesity, and liver disease, Gastroenterology, 115, 997, 10.1016/S0016-5085(98)70272-0

Harrison, 2002, Nonalcoholic Steatohepatitis: what we know in the new millennium, Am J Gastroenterol, 97, 2714

Adams, 2005, The natural history of nonalcoholic fatty liver, Gastroenteroloy, 129, 113, 10.1053/j.gastro.2005.04.014

Hussein, 2007, Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH), Dig Dis Sci, 52, 2512, 10.1007/s10620-006-9631-1

Harrison, 2003, Vitamin E and C treatment improves fibrosis in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x

Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4

Lindor, 2004, Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial, Hepatology, 39, 770, 10.1002/hep.20092

Merat, 2003, Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study, J Clin Gastroenterol, 36, 266, 10.1097/00004836-200303000-00015

Deushi, 2007, Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome, FEBS Lett, 581, 5664, 10.1016/j.febslet.2007.11.023

Yokohama, 2004, Therapeutic efficacy of an antiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis, Hepatology, 40, 1222, 10.1002/hep.20420

Bugianesi, 2005, A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease, Am J Gastroenterol, 100, 1082, 10.1111/j.1572-0241.2005.41583.x

Belfort, 2006, A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis, N Engl J Med, 355, 2297, 10.1056/NEJMoa060326

Ding, 2006, Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice, Hepatology, 43, 173, 10.1002/hep.21006

Georgescu, 2007, Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a Preliminary Study, J Gastrointestinal Liver Dis, 16, 39

Gomez-Dominguez, 2006, A pilot study of atorvastatin treatment in dyslipdemidic, non-alcoholic fatty liver patients, Aliment Pharmacol Ther, 23, 1643, 10.1111/j.1365-2036.2006.02926.x

Rallidis, 2004, Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Letter to the Editor, Artherosclerosis, 174, 193, 10.1016/j.atherosclerosis.2004.01.008

Brunt, 1999, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions, Am J Gastroenterol, 94, 2467, 10.1111/j.1572-0241.1999.01377.x

Sridevi, 2007, Simvastatin (40 mg/d), adiponectin levels, and insulin sensitivity in subjects with metabolic syndrome, Am J Cardiol, 100, 1397, 10.1016/j.amjcard.2007.06.028

Bravo, 2001, Liver biopsy, N Engl J Med, 344, 495, 10.1056/NEJM200102153440706

Leclercq, 2000, CYP2E1 and CYP4A as microsomal catalyst of lipid peroxides in murine nonalcoholic steatohepatitis, J Clin Invest, 105, 1067, 10.1172/JCI8814

Kern, 1995, The expression of tumor necrosis factor in human adipose tissue. Regulation of obesity, weight loss, and relationship to lipoprotein lipase, J Clin Invest, 95, 2111, 10.1172/JCI117899

Klover, 2003, Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice, Diabetes, 52, 2784, 10.2337/diabetes.52.11.2784

Tsochatzis, 2006, The evolving role of leptin and adiponectin in chronic liver diseases, Am J Gastroenterol, 101, 2629, 10.1111/j.1572-0241.2006.00848.x

Anania, 2007, Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease, Gastroenterol, 132, 2191, 10.1053/j.gastro.2007.03.055

Chitturi, 2002, Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?, Hepatology, 36, 403, 10.1053/jhep.2002.34738

Nakao, 2002, Association between nonalcoholic fatty liver, markers of obesity, and serum leptin levels in young adults, Am J Gastroenterol, 97, 1796, 10.1111/j.1572-0241.2002.05846.x

Hui, 2004, Beyond insulin resistance in NASH: TNF-alpha or adiponectin?, Hepatology, 40, 46, 10.1002/hep.20280

Targher, 2006, Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease, Clin Endocrinology, 64, 679, 10.1111/j.1365-2265.2006.02527.x

Shepherd, 1995, For the West of Scotland Coronary Prevention Study Group: prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, 1301, 10.1056/NEJM199511163332001

Devaraj, 2006, Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome, J Clin Endocrinol Metab, 91, 4489, 10.1210/jc.2006-0299

Zhao, 2005, Atorvastatin reduces serum leptin concentration in hypercholesterolemic rabbits, Clin Chim Acta, 360, 133, 10.1016/j.cccn.2005.04.021

Blanco-Colio, 2008, Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk, Eur J Pharmacol, 586, 259, 10.1016/j.ejphar.2008.02.042

Chu, 2008, Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes, J Endocrinol Invest, 31, 42, 10.1007/BF03345565

Chan, 2004, A comparative study of atorvastatin and simvastatin as monotherapy for mixed hyperlipidaemia in Type 2 diabetic patients, Diabetes Res Clin Prac, 66, 97, 10.1016/j.diabres.2004.06.007